Sangamo Therapeutics, Inc.
ENGINEERING AAV

Last updated:

Abstract:

The present disclosure provides methods and compositions to develop AAV capsids with a desired characteristic compared to a natural AAV serotype. These capsids are useful, for example, for the delivery of genome engineering molecules and gene therapy molecules for the treatment of a subject in need thereof.

Status:
Application
Type:

Utility

Filling date:

24 Apr 2020

Issue date:

26 Nov 2020